Name | Number of supported studies | Average coverage | |
---|---|---|---|
ciliated cell | 7 studies | 24% ± 4% |
Insufficient scRNA-seq data for expression of GAS2L2 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
lung | 86% | 316.21 | 497 / 578 | 28% | 1.47 | 326 / 1155 |
brain | 95% | 124.64 | 2504 / 2642 | 14% | 0.61 | 101 / 705 |
ureter | 0% | 0 | 0 / 0 | 100% | 1.53 | 1 / 1 |
breast | 80% | 77.02 | 365 / 459 | 15% | 0.40 | 164 / 1118 |
thymus | 68% | 29.65 | 444 / 653 | 20% | 0.50 | 119 / 605 |
adipose | 74% | 58.49 | 896 / 1204 | 0% | 0 | 0 / 0 |
muscle | 64% | 146.70 | 516 / 803 | 0% | 0 | 0 / 0 |
esophagus | 52% | 34.37 | 751 / 1445 | 8% | 0.22 | 14 / 183 |
skin | 58% | 23.16 | 1053 / 1809 | 0% | 0.02 | 2 / 472 |
stomach | 48% | 13.86 | 174 / 359 | 1% | 0.02 | 2 / 286 |
prostate | 39% | 17.04 | 95 / 245 | 5% | 0.19 | 26 / 502 |
kidney | 33% | 12.66 | 29 / 89 | 11% | 0.31 | 99 / 901 |
pancreas | 23% | 4.94 | 74 / 328 | 21% | 0.80 | 37 / 178 |
uterus | 20% | 91.20 | 34 / 170 | 19% | 0.95 | 89 / 459 |
intestine | 37% | 11.20 | 357 / 966 | 2% | 0.08 | 10 / 527 |
ovary | 10% | 4.35 | 18 / 180 | 22% | 0.99 | 95 / 430 |
bladder | 14% | 4.05 | 3 / 21 | 15% | 0.50 | 75 / 504 |
heart | 22% | 7.06 | 190 / 861 | 0% | 0 | 0 / 0 |
blood vessel | 19% | 11.95 | 258 / 1335 | 0% | 0 | 0 / 0 |
spleen | 15% | 2.66 | 36 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 9% | 0.11 | 4 / 45 |
adrenal gland | 3% | 0.79 | 9 / 258 | 0% | 0.01 | 1 / 230 |
liver | 4% | 0.96 | 8 / 226 | 0% | 0 | 0 / 406 |
lymph node | 0% | 0 | 0 / 0 | 3% | 0.04 | 1 / 29 |
peripheral blood | 2% | 1.79 | 18 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0031110 | Biological process | regulation of microtubule polymerization or depolymerization |
GO_0060296 | Biological process | regulation of cilium beat frequency involved in ciliary motility |
GO_1904825 | Biological process | protein localization to microtubule plus-end |
GO_0051764 | Biological process | actin crosslink formation |
GO_0045745 | Biological process | positive regulation of G protein-coupled receptor signaling pathway |
GO_0001578 | Biological process | microtubule bundle formation |
GO_0035371 | Cellular component | microtubule plus-end |
GO_0001725 | Cellular component | stress fiber |
GO_0036064 | Cellular component | ciliary basal body |
GO_0005886 | Cellular component | plasma membrane |
GO_0005884 | Cellular component | actin filament |
GO_0005737 | Cellular component | cytoplasm |
GO_0001965 | Molecular function | G-protein alpha-subunit binding |
GO_0051015 | Molecular function | actin filament binding |
GO_0008093 | Molecular function | cytoskeletal anchor activity |
GO_0005515 | Molecular function | protein binding |
GO_0008017 | Molecular function | microtubule binding |
Gene name | GAS2L2 |
Protein name | GAS2-like protein 2 (GAS2-related protein on chromosome 17) (Growth arrest-specific protein 2-like 2) |
Synonyms | GAR17 |
Description | FUNCTION: Involved in the cross-linking of microtubules and microfilaments . Regulates microtubule dynamics and stability by interacting with microtubule plus-end tracking proteins, such as MAPRE1, to regulate microtubule growth along actin stress fibers . Enhances ADORA2-mediated adenylyl cyclase activation by acting as a scaffold to recruit trimeric G-protein complexes to ADORA2A (By similarity). Regulates ciliary orientation and performance in cells located in the airway . . |
Accessions | Q8NHY3 ENST00000604641.6 [Q8NHY3-1] |